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Abstract
Background:  Combination therapy has become a new paradigm in malaria treatment.
Amodiaquine is a common partner drug in different malaria combination therapies used or
investigated in sub-Saharan Africa, but data on its efficacy as a single drug are scarce.
Methods:  The objective of the study was to determine the efficacy of amodiaquine against
falciparum malaria in neighbouring rural and urban areas of north-western Burkina Faso. The study
was designed as an uncontrolled trial in children aged 6–59 months with uncomplicated falciparum
malaria in the Nouna Health District.
Results: During the rainy season 2005, 117 children were enrolled, 62 from the rural and 55 from
the urban study area. The crude adequate clinical and parasitological response (ACPR) rate was
103/117 (88%) by day 14 but decreased to 28/117 (24%) by day 28. After PCR correction for
reinfections, ACPR rates were 108/117 (92%) and 71/117 (61%) by day 14 and day 28, respectively.
There were no significant differences in efficacy between urban and rural areas. The Plasmodium
falciparum crt K76T mutation not predict AQ failure, but was selected in parasites re-appearing
following treatment. No serious adverse events occurred and only 16 other adverse events were
recorded.
Conclusion: Compared to chloroquine, amodiaquine is more effective against uncomplicated
falciparum malaria in Burkina Faso. However, a considerable degree of amodiaquine resistance
already exists and it is currently unclear how this resistance will develop when amodiaquine in
combination with other drugs is used on a large scale.
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Background
In sub-Saharan African (SSA), the basis of malaria control
remains early diagnosis and prompt treatment with effec-
tive drugs [1]. This strategy is now complicated by increas-
ing resistance of Plasmodium falciparum to existing and
affordable first-line drugs such as chloroquine (CQ) or
sulphadoxine/pyrimethamine (SP) in most SSA countries
[1-3]. Combination treatment has become a new para-
digm in malaria control, with the particular aim to delay
and possibly reverse the development of drug resistance
[4-9]. Artemisinin-based combination treatment (ACT)
involving a variety of partner drugs has proved highly
effective in a number of field trials [10-21]. However, the
inexpensive combination of sulphadoxine/pyrimeth-
amine plus amodiaquine (AQ) has recently been shown in
a number of countries to be of comparable efficacy under
the current epidemiological situation in SSA [10,19,22-
28].
In Burkina Faso, in vivo CQ resistance was first reported in
1988 and clinical failure rates in children with uncompli-
cated malaria were around 5% in the early 1990s [29].
More recent data indicate that CQ in north-western
Burkina Faso has gradually lost efficacy and now suffers
treatment failure rates of partly more than 50% by day 14,
with marked differences between rural and urban areas
[30-32].
Amodiaquine has been reported to remain remarkably
effective in many countries of SSA and in particular in
West Africa despite emerging CQ resistance [11,27,33-
36]. This has also been documented for north-western
Burkina Faso [27,35,36]. It is thus considered as a useful
partner drug in both, ACT and in non-ACT. In Burkina
Faso, the first-line treatment against uncomplicated
malaria has been changed in 2005 to ACT, including
artesunate (AS)-AQ [37]. Moreover, the potential of AQ as
a partner drug in methylene blue-based combination ther-
apies is currently investigated in the Nouna Health Dis-
trict of Burkina Faso [31,38]. Against this background, the
efficacy of amodiaquine monotherapy was tested in this
study.
Materials and methods
Study area
The study was conducted from September to November
2005 in the research zone of the Centre de Recherche en
Santé de Nouna (CRSN) in Nouna Health District, north-
western Burkina Faso. The Nouna area is a dry orchard
savannah, populated mainly by subsistence farmers of dif-
ferent ethnic groups. Malaria is holoendemic but highly
seasonal with most cases occurring during or briefly after
the rainy season which lasts from June until October [39].
Formal health services are limited to a few rural health
centres and the district hospital in Nouna town (25,000
population). CQ as well as SP were shown to be still quite
effective in the rural, but not in the urban CRSN study area
[30,40]. Despite an official policy change from CQ to ACT
as national malaria first-line therapy in early 2005, CQ
has remained the main drug used for fever treatment in
the area until today [37].
Study design and objectives
The study was designed as an uncontrolled efficacy trial in
two different areas (urban and rural) of Nouna Health
District. The study was open label, with blinding only for
the laboratory technicians being responsible for parasite
determination in blood smears.
The primary objective of the study was to determine and
compare the day 14 efficacy of AQ in the treatment of
young children with uncomplicated falciparum malaria in
the rural and urban CRSN study area. Secondary objec-
tives were to determine and compare the day 28 efficacy
of AQ in the rural and urban CRSN study area and to
determine the safety of AQ in the treatment of young chil-
dren with uncomplicated falciparum malaria in Burkina
Faso.
Patients and study procedures
After information of the study communities, mothers
with febrile young children were invited for examination
by the study team to specific fever measurement points
(public buildings). Out of 420 children screened, a total
of 117 children were enrolled, 62 from two purposely
(good accessibility) chosen villages in 10 and 20 km dis-
tance from Nouna town respectively, and 55 from two
randomly chosen city quarters of Nouna town. It was ini-
tially planned to include 120 children, 60 from the urban
and 60 from the rural study area. This sample size would
allow for a 20% loss to follow-up during the determina-
tion of an overall 40% failure rate (95% confidence level)
at day 28 at a precision of 10%, as well as the detection of
a major difference in AQ resistance between the rural and
urban study areas.
Inclusion criteria were: age 6–59 months, uncomplicated
falciparum malaria (axillary temperature ≥ 37.5°C and ≥
2,000 P. falciparum asexual parasites per μl blood), and
written informed consent given by the parents/caretakers.
Exclusion criteria were complicated or severe malaria
(repeated vomiting, seizures or other neurological impair-
ment, haemoglobin < 7 g/dl or haematocrit < 21%), any
apparent significant disease (e. g. pneumonia, meningitis,
hepatitis, severe diarrhoea, measles, severe malnutrition),
and malaria treatment with western drugs and/or antibi-
otics with antimalarial potency during last seven days
except chloroquine.Malaria Journal 2008, 7:58 http://www.malariajournal.com/content/7/1/58
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Study children received a total dose of 25 mg/kg oral AQ
divided over three days (first and second day: 10 mg/kg,
third day: 5 mg/kg; AQ tablets or syrup, essential drug
stock, Burkina Faso Ministry of Health). All patients were
directly observed for at least 30 min following each treat-
ment. If vomiting occurred once, treatment was repeated.
In case of repeated vomiting, the participant was with-
drawn from the study. Children having fever ≥ 38.5°C
received a standard dose of paracetamol tablets (= aceta-
minophen; 10 mg/kg every six hours) until symptoms
subsided. Follow-up of study children was for 28 days
using a slightly simplified version of the latest WHO pro-
tocol on drug efficacy testing [41]: A finger-prick blood
sample was taken on days 0, 2, 14 and 28. From this,
malaria parasitaemia (thin and thick blood smears) as
well as haematocrit values were determined using stand-
ard CRSN procedures [39]. All malaria slides were exam-
ined by two experienced laboratory technicians
supervised by one of the investigators (BC). Asexual para-
sites were counted on thick blood films against 200 white
blood cells (WBCs) and parasite density was calculated
assuming an average WBC count of 10.000/μL. Slides
were declared negative if no parasites were seen in 400
fields on the thick film. For quality control a 10% random
sample of blood films is regularly cross checked at the lab-
oratory of the Heidelberg School of Tropical Medicine
[39]. Follow-up procedures were carried out through
trained field workers who visited study children at follow-
up days in their homes. Self-reported adverse events were
registered through a standard questionnaire during fol-
low-up visits.
In isolates obtained at recruitment and at treatment fail-
ure, the P. falciparum crt K76T mutation associated with
resistance to CQ, and limitedly AQ [42-47], was deter-
mined at the Institute of Tropical Medicine and Interna-
tional Health in Berlin (Germany) by PCR-RFLP [42].
Isolates comprising both, mutant and wildtype alleles
were considered mutant. Differentiation between recru-
descence and re-infection took place through determina-
tion of msp1 and msp2 genotypes in paired filter paper
blood samples from day 0 and day 14 as well as day 28
and from any other day after day 7 when a child had
developed malaria according to standard methodology
[48].
Statistical analysis
Treatment outcome was categorized according to the lat-
est WHO definitions for early treatment failure (ETF), late
clinical failure (LCF), late parasitological failure (LPF) and
adequate clinical and parasitological response (ACPR)
[41]. Losses to follow-up and dropouts due to other rea-
sons were considered as ETF or LCF depending on the
time of dropout in an intention-to-treat manner.
The primary analysis parameter was the rate of clinical
failures on day 14. Secondary parameters were the rate of
clinical failures on day 28, the rate of early clinical fail-
ures, the rate of late parasitological failures (day 14 and
day 28), and the rate of self-reported adverse events. Effi-
cacy results were compared before and after PCR correc-
tion for reinfections. Data were analysed in the overall
group of study children and for rural (n = 62) and urban
(n = 55) study children separately.
The Chi square test (Chi) was used to compare rates, and
exact binominal 95% confidence intervals (95%CIs) were
calculated. The non parametric Wilcoxon-Mann-Whitney
test (WMW) was applied to compare metric or ordinal
data. The McNemar test was used to compare the propor-
tions of pfcrt K76T at recruitment and at treatment failure.
The statistical calculation was performed with SAS release
8.02 (SAS® Institute Inc, Cary, NC, USA).
Ethical aspects
The study protocol was approved by the local Ethics Com-
mittee in Burkina Faso.
Results
Study group characteristics
117 children with uncomplicated malaria were enrolled,
62 children from the rural and 55 from the urban study
area, respectively (Table 1). The analysis is based on these
117 children. This is the a priori defined full analysis set
(FAS) for the intention to treat analysis. There was no dif-
ference in the distribution of sex between the children
from rural and urban area but children from the urban
area were younger compared to children from the rural
area (means, 26.4 months vs. 33.8 months, P < 0.001).
Roughly one quarter of children had been treated for the
current disease episode with CQ prior to inclusion, with
no major differences between children of urban and rural
residence. More children of the urban (63%) compared to
the rural area (46%) carried parasites with the pfcrt K76T
mutation (P = 0.06). There were six losses to follow-up, all
but one were from the urban study area. The reason for the
five urban cases was withdrawal by the parents who were
dissatisfied with repeated blood taking. The reason for the
rural case was a treated fever episode during follow-up
without malaria parasitaemia.
Safety of study drugs
There was no serious adverse event and no death over the
28 days follow-up period. Reported minor adverse events
were 16 overall, eight in the rural and eight in the urban
study children. Gastroenteritis was the main complaint in
seven of the study children.Malaria Journal 2008, 7:58 http://www.malariajournal.com/content/7/1/58
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Efficacy of study drugs
There was no ETF. The PCR-uncorrected rate of ACPR was
103/117 (88%) in the overall study group by day 14. This
figure decreased to 28/117 (24%) by day 28. After PCR
correction for re-infections, rates of ACPR were 108/117
(92%) and 71/117 (61%) by day 14 and day 28 respec-
tively (Table 2 and Table 3). There were no significant dif-
ferences in efficacy parameters between urban and rural
study children.
Association of treatment outcome with pfcrt K76T
Pfcrt K76T did not predict AQ treatment failure: children
harbouring parasites with this mutation revealed a PCR-
uncorrected (day 28) rate of ACPR of 26% (15/57) as
compared to 25% (13/59) among children infected with
wild-type parasites (P = 0.88; withdrawals excluded from
analysis). Correction for re-infections did not change this
finding (70%, 40/57 vs. 60% 31/52, P = 0.25). However,
all (77/77) parasites isolated from children at AQ treat-
ment failure exhibited the pfcrt K76T mutation as com-
pared to 52% (40/77) at baseline (P < 0.0001). This was
true for recrudescent infections (n = 33) and re-infections
(n = 41; both, P = 0.0001).
Discussion
The main finding from this study is that AQ is more effec-
tive than CQ in Burkina Faso but already affected by a
considerable degree of drug resistance. CQ resistance has
increased rapidly over the last couple of years in the
Nouna Health District as in most of the country with
more than 50 percent of all treatments in young children
documented to have failed already by day 14 [31,37]. In
comparison, AQ performs substantially better with a day
14 rate of APCR of 92 percent as observed in this study.
This finding confirms the superiority of AQ in many SSA
areas with intense CQ resistance [11,27,33,34,43]. How-
ever, AQ treatment was associated with a high rate of re-
infections during follow-up, and by day 28, the PCR-cor-
Table 1: Baseline characteristics (D0)
Characteristic Rural area (n = 62) Urban area (n = 55)
Male 31 (50%) 25 (45%)
Age [months]
- Mean 33.8 26.4
- Min, Max 6.0, 59.0 7.0, 48.0
Prior treatment of current disease episode with chloroquine 15 (24%) 17 (31%)
Haematocrit [%]
- Mean 29.5 28.5
- Min, Max 22.0, 40.0 22.0, 36.0
P. falciparum trophozoites [/μl]
- Median 16.000 18.000
- Min, Max 2.300, 175.000 2.000, 200.000
Fever (°C)
- Mean 38.1 38.2
- Min, Max 37.5, 40.2 37.5, 39.5
Pfcrt codon 76 wildtype 33/61 (54%) 19/52 (37%)
Table 2: Treatment outcomes at D14
Treatment outcome (No, %) [95 CI]
Rural area (n = 62) Urban area (n = 55) Total (n = 117)
ETF 0 (0%) [0–6%] 0 (0%) [0–6%] 0 (0%) [0–3%]
LCF
- Recrudescence 0 (0%) [0–6%] 5 (9%) [3–20%] 5 (4%) [1–10%]
- New infection 0 (0%) [0–6%] 1 (2%) [0–10%] 1 (1%) [0–5%]
- No genotyping results 1 (2%) [0–9%] 0 (0%) [0–6%] 1 (1%) [0–5%]
LPF
- Recrudescence 1 (2%) [0–9%] 1 (2%) [0–10%] 2 (2%) [0–6%]
- New infection 2 (3%) [0–11%] 2 (4%) [0–13%] 4 (3%) [1–9%]
- No genotyping results 1 (2%) [0–9%] 0 (0%) [0–6%] 1 (1%) [0–5%]
ACPR 57 (92%) [82–97%] 46 (84%) [71–92%] 103 (88%) [81–93%]
ACPR (pcr-corrected) 58 (94%) [84–98%] 50 (91%) [80–97%] 108 (92%) [86–96%]Malaria Journal 2008, 7:58 http://www.malariajournal.com/content/7/1/58
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rected rate of APCR was reduced to 61 percent. This not
only supports the importance of sufficiently long follow-
up periods in antimalarial treatment trials [43] but also
points to an established low-level AQ resistance in the
area.
In urban western Burkina Faso, AQ achieves uncorrected
and PCR-corrected cure rates of 82% [95%CI, 77–86%]
and 92% [88–95%], respectively, during four weeks of fol-
low-up [27], which clearly contrasts with the figures of
24% [17–33%] and 61% [51–70] observed in the current
study. The present study had a limited sample size and,
consequently, wide 95% confidence intervals, but this dif-
ference appears to not to be due to chance. However, at
present, the reason for this discrepancy remains obscure.
Aggravation of AQ resistance over time, population differ-
ences e.g. in access to (pre)-treatment, and varying trans-
mission intensities might be involved. The vast majority
of treatment failures in the present study occurred after
day 14, and in roughly half of the failures, exclusively new
parasite genotypes were detected indicating new infec-
tions. This proportion might even be higher, and conse-
quently the actual cure rate better, considering a recent
report illustrating that in highly endemic areas, a consid-
erable number of new infections might be misclassified as
recrudescences when applying conventional genotyping
protocols [49]. In a previous trial in the study area,
marked differences in the efficacy of CQ were observed
between rural and urban settings with failure rates and the
proportion of parasites exhibiting pfcrt K76T being higher
in the latter [32]. This finding entailed the study design of
the current trial. However, cure rates of AQ were observed
to be even slightly higher in urban as compared to rural
areas. Yet, this difference was marginal, the 95%CIs of the
respective efficacy rates overlapped, and the present study
had statistical power to detect only major differences. In
the study area, the prevalence of pfcrt K76T is still rela-
tively low, and similar to previous studies, pfcrt K76T did
not predict AQ treatment failure but was selected among
parasites re-appearing following treatment [44,45,47].
Recent evidence suggests particular pfmdr1 haplotypes of
P. falciparum to be associated with AQ resistance [50]. In
ongoing work, it is examined whether such could explain
the observed unsatisfactory cure rate of AQ observed in
the present study.
Efficacy and useful therapeutic life span of any antimalar-
ial drug combination critically depend on the choice of
the partner drugs and preexisting resistance patterns
[12,51]. As AQ is still effective in most of SSA and as it is
a drug considered sufficiently safe for malaria first-line
therapy, it will be used both in ACT as well as in alterna-
tive malaria combination therapies. AS-AQ is now availa-
ble as a fixed dose combination and has been chosen as
one of two first-line malaria drugs for Burkina Faso [37].
Moreover, AQ was shown repeatedly in Burkina Faso as
well as in other SSA countries to be very effective in com-
bination with SP [10,19,22-28]. However, mainly for
political reasons it was never employed in Burkina Faso
despite such promising findings [37]. It is furthermore
considered as a promising partner drug in combination
with methylene blue [52]. However, AQ resistance exists
in Burkina Faso and it is currently not clear how this resist-
ance will develop when AQ in combination with other
drugs is used on a large scale. Of particular concern, the
combination of a high proportion of re-infections follow-
ing AQ treatment and selection of a marker of drug resist-
ance in treatment failures observed in this study reflects
exposure of recrudescent and newly acquired parasites to
low, subcurative AQ concentrations and might cause sub-
sequent selection for resistance. This, in turn, would
threaten the principle of mutual protection from resist-
ance development in combination treatment.
Table 3: Treatment outcomes at D28
Treatment outcome (No, %) [95 CI]
Rural area (n = 62) Urban area (n = 55) Total (n = 117)
ETF 0 (0%) [0–6%] 0 (0%) [0–6%] 0 (0%) [0–3%]
LCF
- Recrudescence 9 (15%) [7–26%] 11 (20%) [10–33%] 20 (17%) [11–25%]
- New infection 5 (8%) [3–18%] 7 (13%) [5–24%] 12 (10%) [5–17%]
- No genotyping results 2 (3%) [0–11%] 2 (4%) [0–13%] 4 (3%) [1–9%]
LPF
- Recrudescence 14 (23%) [13–35%] 5 (9%) [3–20%] 19 (16%) [10–24%]
- New infection 17 (27%) [17–40%] 14 (25%) [15–39%] 31 (26%) [19–35%]
- No genotyping results 2 (3%) [0–11%] 1 (2%) [0–10%] 3 (3%) [1–7%]
ACPR 13 (21%) [12–33%] 15 (27%) [16–41%] 28 (24%) [17–33%]
ACPR (PCR-corrected) 35 (56%) [43–69%] 36 (65%) [51–78%] 71 (61%) [51–70%]Malaria Journal 2008, 7:58 http://www.malariajournal.com/content/7/1/58
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Conclusion
In this trial from north-western Burkina Faso, AQ treat-
ment of children with uncomplicated malaria achieved an
unsatisfactory cure rate of 61%. Impaired AQ efficacy,
may shorten the useful life span of the first-line drug AQ-
AS and of further AQ-based combination therapies. Con-
tinued monitoring of the efficacy of AQ is warranted.
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